25 XP   0   0   10

BioLine RX Ltd
Buy, Hold or Sell?

Let's analyse BioLine RX Ltd together

PenkeI guess you are interested in BioLine RX Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of BioLine RX Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about BioLine RX Ltd

I send you an email if I find something interesting about BioLine RX Ltd.

Quick analysis of BioLine RX Ltd (30 sec.)










What can you expect buying and holding a share of BioLine RX Ltd? (30 sec.)

How much money do you get?

How much money do you get?
ILA0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
ILA4.44
Expected worth in 1 year
ILA-9.90
How sure are you?
25.0%

+ What do you gain per year?

Total Gains per Share
ILA-14.34
Return On Investment
-50.7%

For what price can you sell your share?

Current Price per Share
ILA28.30
Expected price per share
ILA24.00 - ILA34.90
How sure are you?
50%

1. Valuation of BioLine RX Ltd (5 min.)




Live pricePrice per Share (EOD)

ILA28.30

Intrinsic Value Per Share

ILA-141.11 - ILA-165.89

Total Value Per Share

ILA-136.67 - ILA-161.44

2. Growth of BioLine RX Ltd (5 min.)




Is BioLine RX Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$13.1m$60.8m-$29.8m-96.2%

How much money is BioLine RX Ltd making?

Current yearPrevious yearGrowGrow %
Making money-$13.1m-$5.8m-$7.2m-55.2%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of BioLine RX Ltd (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

What can you expect buying and holding a share of BioLine RX Ltd? (5 min.)

Welcome investor! BioLine RX Ltd's management wants to use your money to grow the business. In return you get a share of BioLine RX Ltd.

What can you expect buying and holding a share of BioLine RX Ltd?

First you should know what it really means to hold a share of BioLine RX Ltd. And how you can make/lose money.

Speculation

The Price per Share of BioLine RX Ltd is ILA28.30. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of BioLine RX Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in BioLine RX Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ILA4.44. Based on the TTM, the Book Value Change Per Share is ILA-3.59 per quarter. Based on the YOY, the Book Value Change Per Share is ILA-1.30 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ILA0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of BioLine RX Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ILA% of Price per ShareILA% of Price per ShareILA% of Price per ShareILA% of Price per ShareILA% of Price per Share
Usd Eps-0.01-0.1%-0.02-0.1%-0.010.0%-0.010.0%-0.010.0%
Usd Book Value Change Per Share-0.010.0%-0.010.0%0.000.0%0.000.0%0.000.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.010.0%-0.010.0%0.000.0%0.000.0%0.000.0%
Usd Price Per Share0.13-0.08-0.09-0.16-0.80-
Price to Earnings Ratio-2.22--1.30--4.57--6.73--12.75-
Price-to-Total Gains Ratio-17.99--9.63--36.39-20.17--110.84-
Price to Book Ratio10.85-4.70-1.58-4.68-16.83-
Price-to-Total Gains Ratio-17.99--9.63--36.39-20.17--110.84-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.076976
Number of shares12991
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.010.00
Usd Total Gains Per Share-0.010.00
Gains per Quarter (12991 shares)-126.70-16.41
Gains per Year (12991 shares)-506.81-65.64
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-507-5170-66-76
20-1014-10240-131-142
30-1520-15310-197-208
40-2027-20380-263-274
50-2534-25450-328-340
60-3041-30520-394-406
70-3548-35590-459-472
80-4054-40660-525-538
90-4561-45730-591-604
100-5068-50800-656-670

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.028.012.00.0%1.029.037.01.5%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%5.015.00.025.0%10.030.00.025.0%17.050.00.025.4%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.067.00.0%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%5.015.00.025.0%10.030.00.025.0%17.050.00.025.4%

Fundamentals of BioLine RX Ltd

About BioLine RX Ltd

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; and MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer, as well as licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Modi'in, Israel.

Fundamental data was last updated by Penke on 2024-03-20 11:56:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of BioLine RX Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit BioLine RX Ltd earns for each 1 of revenue.

  • Above 10% is considered healthy but always compare BioLine RX Ltd to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that 0.00 for each 1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of BioLine RX Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--159.2%+159.2%
TTM--202.3%+202.3%
YOY--263.0%+263.0%
5Y--452.4%+452.4%
10Y--589.0%+589.0%
1.1.2. Return on Assets

Shows how efficient BioLine RX Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare BioLine RX Ltd to the Biotechnology industry mean.
  • -30.3% Return on Assets means that BioLine RX Ltd generated -0.30 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of BioLine RX Ltd:

  • The MRQ is -30.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -21.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-30.3%TTM-21.8%-8.6%
TTM-21.8%YOY-7.8%-13.9%
TTM-21.8%5Y-13.0%-8.7%
5Y-13.0%10Y-8.7%-4.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-30.3%-12.5%-17.8%
TTM-21.8%-12.2%-9.6%
YOY-7.8%-11.2%+3.4%
5Y-13.0%-13.3%+0.3%
10Y-8.7%-14.6%+5.9%
1.1.3. Return on Equity

Shows how efficient BioLine RX Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare BioLine RX Ltd to the Biotechnology industry mean.
  • -122.0% Return on Equity means BioLine RX Ltd generated -1.22 for each 1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of BioLine RX Ltd:

  • The MRQ is -122.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -63.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-122.0%TTM-63.1%-58.9%
TTM-63.1%YOY-9.9%-53.2%
TTM-63.1%5Y-26.2%-36.9%
5Y-26.2%10Y-15.6%-10.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-122.0%-16.0%-106.0%
TTM-63.1%-15.8%-47.3%
YOY-9.9%-13.9%+4.0%
5Y-26.2%-18.2%-8.0%
10Y-15.6%-19.1%+3.5%

1.2. Operating Efficiency of BioLine RX Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient BioLine RX Ltd is operating .

  • Measures how much profit BioLine RX Ltd makes for each 1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare BioLine RX Ltd to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated 0.00  for each 1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of BioLine RX Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--299.5%+299.5%
TTM--208.5%+208.5%
YOY--280.2%+280.2%
5Y--459.9%+459.9%
10Y--596.9%+596.9%
1.2.2. Operating Ratio

Measures how efficient BioLine RX Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are 0.00 for each 1 in net sales.

Let's take a look of the Operating Ratio trends of BioLine RX Ltd:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.817-2.817
TTM-3.181-3.181
YOY-3.609-3.609
5Y-5.554-5.554
10Y-7.396-7.396

1.3. Liquidity of BioLine RX Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if BioLine RX Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.96 means the company has 1.96 in assets for each 1 in short-term debts.

Let's take a look of the Current Ratio trends of BioLine RX Ltd:

  • The MRQ is 1.956. The company is able to pay all its short-term debts. +1
  • The TTM is 3.324. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ1.956TTM3.324-1.367
TTM3.324YOY5.802-2.479
TTM3.3245Y4.162-0.838
5Y4.16210Y3.741+0.421
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.9563.987-2.031
TTM3.3244.440-1.116
YOY5.8025.569+0.233
5Y4.1626.158-1.996
10Y3.7416.492-2.751
1.3.2. Quick Ratio

Measures if BioLine RX Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare BioLine RX Ltd to the Biotechnology industry mean.
  • A Quick Ratio of 1.24 means the company can pay off 1.24 for each 1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of BioLine RX Ltd:

  • The MRQ is 1.239. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 2.427. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.239TTM2.427-1.188
TTM2.427YOY4.344-1.918
TTM2.4275Y3.145-0.718
5Y3.14510Y3.056+0.089
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2393.653-2.414
TTM2.4274.158-1.731
YOY4.3445.515-1.171
5Y3.1456.012-2.867
10Y3.0566.206-3.150

1.4. Solvency of BioLine RX Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of BioLine RX Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare BioLine RX Ltd to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.75 means that BioLine RX Ltd assets are financed with 75.2% credit (debt) and the remaining percentage (100% - 75.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of BioLine RX Ltd:

  • The MRQ is 0.752. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.540. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.752TTM0.540+0.212
TTM0.540YOY0.200+0.339
TTM0.5405Y0.350+0.189
5Y0.35010Y0.238+0.112
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7520.336+0.416
TTM0.5400.330+0.210
YOY0.2000.267-0.067
5Y0.3500.367-0.017
10Y0.2380.378-0.140
1.4.2. Debt to Equity Ratio

Measures if BioLine RX Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare BioLine RX Ltd to the Biotechnology industry mean.
  • A Debt to Equity ratio of 302.4% means that company has 3.02 debt for each 1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of BioLine RX Ltd:

  • The MRQ is 3.024. The company is unable to pay all its debts with equity. -1
  • The TTM is 1.520. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ3.024TTM1.520+1.504
TTM1.520YOY0.261+1.259
TTM1.5205Y0.687+0.834
5Y0.68710Y0.420+0.266
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.0240.376+2.648
TTM1.5200.398+1.122
YOY0.2610.334-0.073
5Y0.6870.431+0.256
10Y0.4200.476-0.056

2. Market Valuation of BioLine RX Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every 1 in earnings BioLine RX Ltd generates.

  • Above 15 is considered overpriced but always compare BioLine RX Ltd to the Biotechnology industry mean.
  • A PE ratio of -2.22 means the investor is paying -2.22 for every 1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of BioLine RX Ltd:

  • The EOD is -1.305. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.223. Based on the earnings, the company is expensive. -2
  • The TTM is -1.296. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.305MRQ-2.223+0.918
MRQ-2.223TTM-1.296-0.927
TTM-1.296YOY-4.568+3.272
TTM-1.2965Y-6.729+5.433
5Y-6.72910Y-12.749+6.020
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.305-2.697+1.392
MRQ-2.223-2.422+0.199
TTM-1.296-2.709+1.413
YOY-4.568-4.116-0.452
5Y-6.729-6.257-0.472
10Y-12.749-6.478-6.271
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of BioLine RX Ltd:

  • The EOD is -2.106. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.587. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.549. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.106MRQ-3.587+1.481
MRQ-3.587TTM-2.549-1.038
TTM-2.549YOY-3.979+1.430
TTM-2.5495Y-3.548+0.999
5Y-3.54810Y-1.774-1.774
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.106-3.344+1.238
MRQ-3.587-2.939-0.648
TTM-2.549-3.486+0.937
YOY-3.979-5.592+1.613
5Y-3.548-8.464+4.916
10Y-1.774-8.872+7.098
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of BioLine RX Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 10.85 means the investor is paying 10.85 for each 1 in book value.

Let's take a look of the Price to Book Ratio trends of BioLine RX Ltd:

  • The EOD is 6.368. Based on the equity, the company is overpriced. -1
  • The MRQ is 10.846. Based on the equity, the company is expensive. -2
  • The TTM is 4.702. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD6.368MRQ10.846-4.478
MRQ10.846TTM4.702+6.144
TTM4.702YOY1.581+3.121
TTM4.7025Y4.683+0.019
5Y4.68310Y16.830-12.147
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD6.3682.198+4.170
MRQ10.8462.042+8.804
TTM4.7022.121+2.581
YOY1.5812.907-1.326
5Y4.6833.682+1.001
10Y16.8304.114+12.716
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of BioLine RX Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---2.680-3.586+34%-1.301-51%-0.464-83%-0.314-88%
Book Value Per Share--4.44410.501-58%20.605-78%14.944-70%17.488-75%
Current Ratio--1.9563.324-41%5.802-66%4.162-53%3.741-48%
Debt To Asset Ratio--0.7520.540+39%0.200+275%0.350+115%0.238+216%
Debt To Equity Ratio--3.0241.520+99%0.261+1058%0.687+340%0.420+619%
Dividend Per Share----0%-0%-0%-0%
Eps---5.421-6.061+12%-1.990-63%-3.029-44%-1.903-65%
Free Cash Flow Per Share---3.359-2.858-15%-2.217-34%-2.285-32%-2.285-32%
Free Cash Flow To Equity Per Share---2.175-2.596+19%-0.419-81%-0.034-98%-0.034-98%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.700+43%
Intrinsic Value_10Y_max---165.888--------
Intrinsic Value_10Y_min---141.115--------
Intrinsic Value_1Y_max---10.478--------
Intrinsic Value_1Y_min---10.289--------
Intrinsic Value_3Y_max---36.166--------
Intrinsic Value_3Y_min---34.433--------
Intrinsic Value_5Y_max---67.500--------
Intrinsic Value_5Y_min---62.249--------
Market Cap30750495641.600-70%52373635686.40033276817280.000+57%35830303667.200+46%64163136665.600-18%319742675750.400-84%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio6.368-70%10.8464.702+131%1.581+586%4.683+132%16.830-36%
Pe Ratio-1.305+41%-2.223-1.296-42%-4.568+106%-6.729+203%-12.749+474%
Price Per Share28.300-70%48.20030.625+57%32.975+46%59.050-18%294.263-84%
Price To Free Cash Flow Ratio-2.106+41%-3.587-2.549-29%-3.979+11%-3.548-1%-1.774-51%
Price To Total Gains Ratio-10.561+41%-17.987-9.631-46%-36.394+102%20.174-189%-110.839+516%
Quick Ratio--1.2392.427-49%4.344-71%3.145-61%3.056-59%
Return On Assets---0.303-0.218-28%-0.078-74%-0.130-57%-0.087-71%
Return On Equity---1.220-0.631-48%-0.099-92%-0.262-79%-0.156-87%
Total Gains Per Share---2.680-3.586+34%-1.301-51%-0.464-83%-0.314-88%
Usd Book Value--13134105.07231035998.286-58%60898487.184-78%44166403.328-70%51686288.487-75%
Usd Book Value Change Per Share---0.007-0.010+34%-0.004-51%-0.001-83%-0.001-88%
Usd Book Value Per Share--0.0120.029-58%0.056-78%0.041-70%0.048-75%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.015-0.016+12%-0.005-63%-0.008-44%-0.005-65%
Usd Free Cash Flow---9928079.424-8447317.578-15%-6552552.420-34%-5065540.524-49%-2532770.262-74%
Usd Free Cash Flow Per Share---0.009-0.008-15%-0.006-34%-0.006-32%-0.006-32%
Usd Free Cash Flow To Equity Per Share---0.006-0.007+19%-0.001-81%0.000-98%0.000-98%
Usd Market Cap83641348.145-70%142456289.06790512943.002+57%97458425.975+46%174523731.730-18%869700078.041-84%
Usd Price Per Share0.077-70%0.1310.083+57%0.090+46%0.161-18%0.800-84%
Usd Profit---16023128.184-13115354.922-18%-5881047.048-63%-7992763.942-50%-5145066.160-68%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---0.007-0.010+34%-0.004-51%-0.001-83%-0.001-88%
 EOD+3 -5MRQTTM+13 -16YOY+4 -255Y+2 -2710Y+5 -25

3.2. Fundamental Score

Let's check the fundamental score of BioLine RX Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.305
Price to Book Ratio (EOD)Between0-16.368
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.239
Current Ratio (MRQ)Greater than11.956
Debt to Asset Ratio (MRQ)Less than10.752
Debt to Equity Ratio (MRQ)Less than13.024
Return on Equity (MRQ)Greater than0.15-1.220
Return on Assets (MRQ)Greater than0.05-0.303
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of BioLine RX Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.527
Ma 20Greater thanMa 5030.185
Ma 50Greater thanMa 10030.432
Ma 100Greater thanMa 20034.732
OpenGreater thanClose28.400
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets52,855
Total Liabilities39,721
Total Stockholder Equity13,134
 As reported
Total Liabilities 39,721
Total Stockholder Equity+ 13,134
Total Assets = 52,855

Assets

Total Assets52,855
Total Current Assets28,805
Long-term Assets24,050
Total Current Assets
Cash And Cash Equivalents 7,727
Short-term Investments 18,241
Inventory 1,352
Total Current Assets  (as reported)28,805
Total Current Assets  (calculated)27,320
+/- 1,485
Long-term Assets
Property Plant Equipment 2,023
Long-term Assets  (as reported)24,050
Long-term Assets  (calculated)2,023
+/- 22,027

Liabilities & Shareholders' Equity

Total Current Liabilities14,725
Long-term Liabilities24,996
Total Stockholder Equity13,134
Total Current Liabilities
Short Long Term Debt 3,078
Accounts payable 8,438
Total Current Liabilities  (as reported)14,725
Total Current Liabilities  (calculated)11,516
+/- 3,209
Long-term Liabilities
Long term Debt 8,458
Capital Lease Obligations Min Short Term Debt1,777
Long-term Liabilities  (as reported)24,996
Long-term Liabilities  (calculated)10,235
+/- 14,761
Total Stockholder Equity
Total Stockholder Equity (as reported)13,134
Total Stockholder Equity (calculated)0
+/- 13,134
Other
Capital Stock28,332
Common Stock Shares Outstanding 969,918
Net Debt 3,809
Net Invested Capital 24,670
Net Working Capital 14,080
Property Plant and Equipment Gross 2,023



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-03-312005-12-31
> Total Assets 
20,590
0
21,077
254,539
241,960
233,033
207,883
180,124
153,270
132,417
115,728
74,936
65,252
106,428
159,167
143,894
110,311
154,613
143,661
129,126
123,739
111,660
146,041
130,475
110,942
90,808
112,012
91,042
79,002
69,469
136,488
120,265
114,097
140,827
59,873
58,355
55,031
51,302
48,941
45,680
42,277
38,939
41,118
63,048
66,127
60,965
56,075
52,213
46,400
56,233
67,594
61,958
57,225
53,567
47,171
52,989
46,039
47,290
83,599
91,329
86,905
81,391
74,773
67,838
81,673
76,384
68,646
58,936
52,855
52,85558,93668,64676,38481,67367,83874,77381,39186,90591,32983,59947,29046,03952,98947,17153,56757,22561,95867,59456,23346,40052,21356,07560,96566,12763,04841,11838,93942,27745,68048,94151,30255,03158,35559,873140,827114,097120,265136,48869,46979,00291,042112,01290,808110,942130,475146,041111,660123,739129,126143,661154,613110,311143,894159,167106,42865,25274,936115,728132,417153,270180,124207,883233,033241,960254,53921,077020,590
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
147,047
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
36,101
31,648
53,663
55,847
50,376
45,544
42,797
37,104
31,978
41,649
36,207
31,702
28,210
22,140
28,169
21,423
22,880
59,352
67,072
62,846
57,404
50,941
44,103
57,942
52,001
44,327
34,692
28,805
28,80534,69244,32752,00157,94244,10350,94157,40462,84667,07259,35222,88021,42328,16922,14028,21031,70236,20741,64931,97837,10442,79745,54450,37655,84753,66331,64836,10100000000000000000000000000147,04700000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
105,890
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,469
2,201
6,946
6,712
5,110
7,810
5,789
4,703
3,404
4,384
4,972
4,885
5,297
5,072
5,523
6,552
16,831
16,047
17,484
14,077
12,990
11,446
14,000
13,105
10,587
9,066
10,104
7,727
7,72710,1049,06610,58713,10514,00011,44612,99014,07717,48416,04716,8316,5525,5235,0725,2974,8854,9724,3843,4044,7035,7897,8105,1106,7126,9462,2012,46900000000000000000000000000105,89000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
33,154
28,167
45,616
48,295
44,373
36,388
35,339
30,300
26,747
36,224
30,256
25,255
22,192
16,109
21,779
14,275
5,756
42,036
48,083
48,128
44,145
39,144
29,146
44,157
40,495
34,221
22,711
18,241
18,24122,71134,22140,49544,15729,14639,14444,14548,12848,08342,0365,75614,27521,77916,10922,19225,25530,25636,22426,74730,30035,33936,38844,37348,29545,61628,16733,15400000000000000000000000000000000000000000
       Net Receivables 
1,329
0
597
1,201
1,019
2,301
1,259
1,885
3,849
5,502
5,748
9,373
0
26,138
40,063
0
9,637
1,019
6,323
6,540
2,113
3,409
1,853
1,765
1,814
1,856
2,581
1,092
875
1,249
793
1,422
222
1,000
641
653
992
291
396
548
303
223
580
541
558
586
782
438
835
1,339
458
528
1,285
613
682
441
327
141
190
668
192
142
190
240
143
0
0
128
0
0128001432401901421926681901413274416826131,2855284581,3398354387825865585415802233035483962919926536411,0002221,4227931,2498751,0922,5811,8561,8141,7651,8533,4092,1136,5406,3231,0199,637040,06326,13809,3735,7485,5023,8491,8851,2592,3011,0191,20159701,329
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,352
1,35200000000000000000000000000000000000000000000000000000000000000000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
25,945
25,751
25,523
25,357
25,031
24,820
24,616
24,410
24,247
24,257
24,059
23,987
23,832
23,735
23,731
24,383
24,319
24,244
24,050
24,05024,24424,31924,38323,73123,73523,83223,98724,05924,25724,24724,41024,61624,82025,03125,35725,52325,75125,94500000000000000000000000000000000000000000000000000
       Property Plant Equipment 
2,211
0
3,709
3,573
3,484
3,792
3,730
5,211
5,078
5,764
5,484
5,124
0
4,404
4,175
0
4,696
4,509
4,350
4,235
4,076
4,211
3,970
3,647
3,420
3,172
2,947
2,871
2,681
2,471
2,404
2,333
2,330
2,804
1,111
2,489
2,962
2,909
2,859
2,770
2,654
2,605
2,540
2,463
2,365
2,505
2,432
2,318
2,197
2,227
3,940
3,763
3,558
3,466
3,263
3,070
2,885
2,696
2,540
2,551
2,354
2,283
2,128
2,031
2,015
2,498
2,358
2,231
2,023
2,0232,2312,3582,4982,0152,0312,1282,2832,3542,5512,5402,6962,8853,0703,2633,4663,5583,7633,9402,2272,1972,3182,4322,5052,3652,4632,5402,6052,6542,7702,8592,9092,9622,4891,1112,8042,3302,3332,4042,4712,6812,8712,9473,1723,4203,6473,9704,2114,0764,2354,3504,5094,69604,1754,40405,1245,4845,7645,0785,2113,7303,7923,4843,5733,70902,211
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,000
1,000
1,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000001,0001,0001,00000000000000000000000000000000000000000000000
       Intangible Assets 
0
0
1,054
122
268
384
1,983
2,798
3,114
3,647
3,205
3,010
0
3,518
3,042
0
1,473
1,352
1,303
1,198
1,178
1,144
1,124
1,091
1,060
1,063
1,056
932
911
878
859
853
837
457
116
117
128
152
157
162
155
181
6,875
6,869
6,855
7,023
7,039
7,035
7,033
21,972
21,950
21,928
21,906
21,891
0
0
0
21,714
0
0
0
21,704
0
0
0
21,885
0
0
0
00021,88500021,70400021,71400021,89121,90621,92821,95021,9727,0337,0357,0397,0236,8556,8696,8751811551621571521281171164578378538598789119321,0561,0631,0601,0911,1241,1441,1781,1981,3031,3521,47303,0423,51803,0103,2053,6473,1142,7981,9833842681221,05400
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,797
25,751
25,523
25,357
25,031
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000025,03125,35725,52325,7511,79700000000000000000000000000000000000000000000000000
> Total Liabilities 
7,825
0
8,334
24,662
26,861
41,185
24,630
25,159
22,248
27,958
37,342
21,221
23,259
44,578
41,230
40,119
32,815
22,653
22,712
23,764
25,020
25,902
41,583
36,656
39,001
34,879
37,995
27,955
28,768
28,783
23,626
19,736
15,086
17,133
5,685
6,539
4,360
3,692
2,939
3,116
3,668
3,912
5,402
5,618
7,102
8,084
7,053
6,027
5,815
14,912
21,706
20,176
18,027
20,187
18,663
23,759
21,231
25,260
18,952
17,436
16,004
13,304
11,360
11,270
26,149
25,543
29,532
37,882
39,721
39,72137,88229,53225,54326,14911,27011,36013,30416,00417,43618,95225,26021,23123,75918,66320,18718,02720,17621,70614,9125,8156,0277,0538,0847,1025,6185,4023,9123,6683,1162,9393,6924,3606,5395,68517,13315,08619,73623,62628,78328,76827,95537,99534,87939,00136,65641,58325,90225,02023,76422,71222,65332,81540,11941,23044,57823,25921,22137,34227,95822,24825,15924,63041,18526,86124,6628,33407,825
   > Total Current Liabilities 
4,561
0
8,292
8,427
9,337
17,414
24,616
25,145
22,234
27,944
37,328
21,207
23,245
44,564
41,230
40,119
32,226
22,191
22,330
23,462
24,799
25,709
27,505
25,318
26,456
24,011
27,227
18,954
15,460
10,444
11,170
9,454
9,638
11,300
4,145
4,152
3,590
3,140
2,559
2,805
3,367
3,661
5,174
5,414
5,526
6,722
6,180
5,338
4,925
6,751
8,135
8,559
10,091
11,968
11,766
11,723
10,476
10,641
10,216
9,917
10,313
9,719
9,098
9,632
8,133
10,679
12,041
12,446
14,725
14,72512,44612,04110,6798,1339,6329,0989,71910,3139,91710,21610,64110,47611,72311,76611,96810,0918,5598,1356,7514,9255,3386,1806,7225,5265,4145,1743,6613,3672,8052,5593,1403,5904,1524,14511,3009,6389,45411,17010,44415,46018,95427,22724,01126,45625,31827,50525,70924,79923,46222,33022,19132,22640,11941,23044,56423,24521,20737,32827,94422,23425,14524,61617,4149,3378,4278,29204,561
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
343
320
296
93
93
93
93
93
895
1,636
2,395
3,164
2,692
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000002,6923,1642,3951,636895939393939329632034300000000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
343
320
296
93
93
93
93
93
895
1,636
2,395
3,164
2,692
2,777
2,867
2,969
3,092
3,220
3,354
3,575
2,757
1,903
1,013
802
1,542
2,558
3,078
3,078
3,0783,0782,5581,5428021,0131,9032,7573,5753,3543,2203,0922,9692,8672,7772,6923,1642,3951,636895939393939329632034300000000000000000000000000000000000000000
       Accounts payable 
3,013
0
6,306
6,465
7,053
13,369
14,742
18,024
15,503
21,831
31,345
14,708
0
21,685
6,452
0
3,615
6,213
3,104
4,311
5,551
11,275
12,188
10,978
11,689
12,283
21,873
15,084
12,564
7,945
6,899
6,397
5,607
6,431
2,614
2,959
2,349
1,910
1,465
1,732
2,274
2,590
3,450
4,262
4,349
5,516
4,941
4,128
3,804
4,493
4,817
4,565
5,303
7,794
7,489
7,396
5,933
5,918
5,756
5,318
5,441
5,567
5,784
7,338
5,829
6,966
7,136
6,733
8,438
8,4386,7337,1366,9665,8297,3385,7845,5675,4415,3185,7565,9185,9337,3967,4897,7945,3034,5654,8174,4933,8044,1284,9415,5164,3494,2623,4502,5902,2741,7321,4651,9102,3492,9592,6146,4315,6076,3976,8997,94512,56415,08421,87312,28311,68910,97812,18811,2755,5514,3113,1046,2133,61506,45221,685014,70831,34521,83115,50318,02414,74213,3697,0536,4656,30603,013
       Other Current Liabilities 
1,548
0
1,986
1,962
2,284
4,045
9,874
7,121
6,731
6,113
5,983
6,499
23,245
22,879
34,778
40,119
28,304
15,671
18,919
18,844
18,941
14,127
15,010
14,086
14,595
11,591
5,300
3,870
2,896
2,499
4,271
3,057
4,031
4,869
1,531
1,193
1,148
1,137
1,001
980
1,000
978
1,631
1,059
1,084
1,113
1,146
1,117
1,028
14
693
927
973
7
1,303
1,260
1,374
3
1,100
1,071
1,128
2
1,264
1,132
1,351
84
0
2,260
0
02,2600841,3511,1321,26421,1281,0711,10031,3741,2601,3037973927693141,0281,1171,1461,1131,0841,0591,6319781,0009801,0011,1371,1481,1931,5314,8694,0313,0574,2712,4992,8963,8705,30011,59114,59514,08615,01014,12718,94118,84418,91915,67128,30440,11934,77822,87923,2456,4995,9836,1136,7317,1219,8744,0452,2841,9621,98601,548
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13,571
11,617
7,936
8,219
6,897
12,036
10,755
14,619
8,736
7,519
5,691
3,585
2,262
1,638
18,016
14,864
17,491
25,436
24,996
24,99625,43617,49114,86418,0161,6382,2623,5855,6917,5198,73614,61910,75512,0366,8978,2197,93611,61713,57100000000000000000000000000000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-343
-320
-296
-93
-93
-93
-93
-93
-895
187
-627
-1,451
-728
1,836
1,830
1,801
1,852
1,738
1,875
1,847
1,894
1,805
1,601
1,658
2,156
2,081
1,964
1,777
1,7771,9642,0812,1561,6581,6011,8051,8941,8471,8751,7381,8521,8011,8301,836-728-1,451-627187-895-93-93-93-93-93-296-320-34300000000000000000000000000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,130
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000001,13000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
12,765
12,765
12,743
229,877
215,099
191,848
183,253
154,965
131,022
104,459
78,386
53,715
41,993
61,850
117,937
103,775
77,496
131,960
120,949
105,362
98,719
85,758
104,458
93,819
71,941
55,929
74,017
63,087
50,234
40,686
112,862
100,529
99,011
123,694
54,188
51,816
50,671
47,610
46,002
42,564
38,609
35,027
35,716
57,430
59,025
52,881
49,022
46,186
40,585
41,321
45,888
41,782
39,198
33,380
28,508
29,230
24,808
22,030
64,647
73,893
70,901
68,087
63,413
56,568
55,524
50,841
39,114
21,054
13,134
13,13421,05439,11450,84155,52456,56863,41368,08770,90173,89364,64722,03024,80829,23028,50833,38039,19841,78245,88841,32140,58546,18649,02252,88159,02557,43035,71635,02738,60942,56446,00247,61050,67151,81654,188123,69499,011100,529112,86240,68650,23463,08774,01755,92971,94193,819104,45885,75898,719105,362120,949131,96077,496103,775117,93761,85041,99353,71578,386104,459131,022154,965183,253191,848215,099229,87712,74312,76512,765
   Common Stock
0
0
0
614
615
618
625
625
625
625
625
625
41,993
1,122
1,235
103,775
1,235
1,236
1,236
1,236
1,236
1,236
1,760
1,760
1,760
1,837
2,225
2,294
2,357
2,414
3,396
3,411
3,411
3,911
1,420
1,448
1,450
1,455
1,459
1,459
1,460
1,513
1,642
2,570
2,809
2,836
2,874
2,920
2,922
3,110
3,928
4,001
4,129
4,692
4,907
8,281
8,281
9,870
18,731
20,496
20,874
21,066
21,066
21,157
27,098
0
0
27,100
0
027,1000027,09821,15721,06621,06620,87420,49618,7319,8708,2818,2814,9074,6924,1294,0013,9283,1102,9222,9202,8742,8362,8092,5701,6421,5131,4601,4591,4591,4551,4501,4481,4203,9113,4113,4113,3962,4142,3572,2942,2251,8371,7601,7601,7601,2361,2361,2361,2361,2361,235103,7751,2351,12241,993625625625625625625618615614000
   Retained Earnings Total Equity000000000000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 000000000000000000000000000000000000000000000000000000000000000000000
   Capital Surplus 000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
442,025
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,153
8,243
8,450
8,811
8,921
9,727
9,927
10,473
10,539
10,775
10,419
10,737
10,716
11,072
11,223
11,419
10,906
12,175
12,531
12,713
12,716
12,874
13,155
13,846
0
0
15,608
0
015,6080013,84613,15512,87412,71612,71312,53112,17510,90611,41911,22311,07210,71610,73710,41910,77510,53910,4739,9279,7278,9218,8118,4508,2439,15300000000000000000000000000442,02500000000000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue--
Gross Profit-0
 
Operating Income (+$)
Gross Profit-
Operating Expense-39,526
Operating Income-39,526-39,526
 
Operating Expense (+$)
Research Development12,847
Selling General Administrative26,640
Selling And Marketing Expenses-
Operating Expense39,52639,487
 
Net Interest Income (+$)
Interest Income1,727
Interest Expense-4,055
Other Finance Cost-26
Net Interest Income-2,354
 
Pretax Income (+$)
Operating Income-39,526
Net Interest Income-2,354
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-52,461-28,945
EBIT - interestExpense = -4,055
-52,461
-48,406
Interest Expense4,055
Earnings Before Interest and Taxes (EBIT)--48,406
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-52,461
Tax Provision--
Net Income From Continuing Ops-52,461-52,461
Net Income-52,461
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-10,5812,354
 

Technical Analysis of BioLine RX Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of BioLine RX Ltd. The general trend of BioLine RX Ltd is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine BioLine RX Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of BioLine RX Ltd.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 28.50 < 34.80 < 34.90.

The bearish price targets are: 27.50 > 26.80 > 24.00.

Tweet this
BioLine RX Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of BioLine RX Ltd. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

BioLine RX Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of BioLine RX Ltd. The current macd is -0.50661119.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the BioLine RX Ltd price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for BioLine RX Ltd. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the BioLine RX Ltd price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
BioLine RX Ltd Daily Moving Average Convergence/Divergence (MACD) ChartBioLine RX Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of BioLine RX Ltd. The current adx is 14.33.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell BioLine RX Ltd shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
BioLine RX Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of BioLine RX Ltd. The current sar is 33.37.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
BioLine RX Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of BioLine RX Ltd. The current rsi is 43.53. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
BioLine RX Ltd Daily Relative Strength Index (RSI) ChartBioLine RX Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of BioLine RX Ltd. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the BioLine RX Ltd price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
BioLine RX Ltd Daily Stochastic Oscillator ChartBioLine RX Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of BioLine RX Ltd. The current cci is -99.17355372.

BioLine RX Ltd Daily Commodity Channel Index (CCI) ChartBioLine RX Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of BioLine RX Ltd. The current cmo is -14.91715519.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
BioLine RX Ltd Daily Chande Momentum Oscillator (CMO) ChartBioLine RX Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of BioLine RX Ltd. The current willr is -81.25.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
BioLine RX Ltd Daily Williams %R ChartBioLine RX Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of BioLine RX Ltd.

BioLine RX Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of BioLine RX Ltd. The current atr is 1.86485552.

BioLine RX Ltd Daily Average True Range (ATR) ChartBioLine RX Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of BioLine RX Ltd. The current obv is -44,259,228.

BioLine RX Ltd Daily On-Balance Volume (OBV) ChartBioLine RX Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of BioLine RX Ltd. The current mfi is 29.05.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
BioLine RX Ltd Daily Money Flow Index (MFI) ChartBioLine RX Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for BioLine RX Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-09STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-11-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-26STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-11-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-10SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-14STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-17STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-24WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-31CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-04CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-08STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-16BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-28ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-29MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-31RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-02-01STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-02-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-12RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-13MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-15STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-18STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-19WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

BioLine RX Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of BioLine RX Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.527
Ma 20Greater thanMa 5030.185
Ma 50Greater thanMa 10030.432
Ma 100Greater thanMa 20034.732
OpenGreater thanClose28.400
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of BioLine RX Ltd with someone you think should read this too:
  • Are you bullish or bearish on BioLine RX Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about BioLine RX Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about BioLine RX Ltd

I send you an email if I find something interesting about BioLine RX Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about BioLine RX Ltd.

Receive notifications about BioLine RX Ltd in your mailbox!